Aldeyra Therapeutics (ALDX) Competitors $5.39 -0.17 (-3.06%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.50 +0.11 (+1.95%) As of 09/12/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALDX vs. WVE, ETNB, TLRY, PGEN, RCUS, NTLA, GPCR, XERS, ABCL, and EVOShould you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include WAVE Life Sciences (WVE), 89BIO (ETNB), Tilray Brands (TLRY), Precigen (PGEN), Arcus Biosciences (RCUS), Intellia Therapeutics (NTLA), Structure Therapeutics (GPCR), Xeris Biopharma (XERS), AbCellera Biologics (ABCL), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. Aldeyra Therapeutics vs. Its Competitors WAVE Life Sciences 89BIO Tilray Brands Precigen Arcus Biosciences Intellia Therapeutics Structure Therapeutics Xeris Biopharma AbCellera Biologics Evotec Aldeyra Therapeutics (NASDAQ:ALDX) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings. Is ALDX or WVE more profitable? Aldeyra Therapeutics' return on equity of -73.63% beat WAVE Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Aldeyra TherapeuticsN/A -73.63% -50.61% WAVE Life Sciences N/A -78.45%-41.51% Which has stronger valuation & earnings, ALDX or WVE? Aldeyra Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAldeyra TherapeuticsN/AN/A-$55.85M-$0.85-6.34WAVE Life Sciences$108.30M10.24-$97.01M-$0.90-7.74 Do institutionals & insiders have more ownership in ALDX or WVE? 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 9.6% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 24.0% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend ALDX or WVE? Aldeyra Therapeutics presently has a consensus target price of $9.50, indicating a potential upside of 76.25%. WAVE Life Sciences has a consensus target price of $20.33, indicating a potential upside of 191.73%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than Aldeyra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67WAVE Life Sciences 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.93 Which has more risk and volatility, ALDX or WVE? Aldeyra Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, WAVE Life Sciences has a beta of -1.15, suggesting that its stock price is 215% less volatile than the S&P 500. Does the media prefer ALDX or WVE? In the previous week, WAVE Life Sciences had 9 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 10 mentions for WAVE Life Sciences and 1 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 1.89 beat WAVE Life Sciences' score of 1.07 indicating that Aldeyra Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aldeyra Therapeutics Very Positive WAVE Life Sciences Positive SummaryWAVE Life Sciences beats Aldeyra Therapeutics on 8 of the 14 factors compared between the two stocks. Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALDX vs. The Competition Export to ExcelMetricAldeyra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$333.02M$2.59B$5.87B$10.13BDividend YieldN/A56.52%5.68%4.60%P/E Ratio-6.3423.5374.5225.93Price / SalesN/A523.61517.44183.79Price / CashN/A171.1637.5660.44Price / Book4.535.3712.166.29Net Income-$55.85M$32.95M$3.28B$270.77M7 Day Performance-3.06%1.28%0.87%3.88%1 Month Performance0.37%6.09%4.96%4.88%1 Year Performance-10.61%-2.15%60.75%26.01% Aldeyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALDXAldeyra Therapeutics2.1745 of 5 stars$5.39-3.1%$9.50+76.3%-12.9%$333.02MN/A-6.3410Positive NewsWVEWAVE Life Sciences4.481 of 5 stars$7.58-8.6%$20.33+168.2%+18.9%$1.32B$108.30M-8.42240Positive NewsETNB89BIO2.7962 of 5 stars$8.57-3.4%$28.00+226.7%-0.2%$1.32BN/A-2.3740Positive NewsTLRYTilray Brands2.6761 of 5 stars$1.12-5.9%$1.94+73.0%-34.1%$1.31B$821.31M-0.482,842Short Interest ↓Gap UpPGENPrecigen4.5651 of 5 stars$4.16-4.6%$8.25+98.3%+282.1%$1.30B$4.34M-9.90190Positive NewsRCUSArcus Biosciences1.8704 of 5 stars$11.43-6.3%$21.14+85.0%-33.9%$1.30B$258M-3.60500Positive NewsNTLAIntellia Therapeutics4.3911 of 5 stars$11.84-1.8%$29.05+145.4%-44.8%$1.29B$57.88M-2.52600Analyst RevisionGPCRStructure Therapeutics3.3486 of 5 stars$20.86-5.5%$75.71+263.0%-48.1%$1.27BN/A-19.87136News CoveragePositive NewsAnalyst RevisionXERSXeris Biopharma3.0442 of 5 stars$7.77-1.0%$7.08-8.8%+161.9%$1.27B$203.07M-37.00290Positive NewsInsider TradeABCLAbCellera Biologics2.6022 of 5 stars$4.17-1.2%$8.00+91.8%+66.8%$1.26B$28.83M-7.58500EVOEvotec1.6843 of 5 stars$3.49+0.3%$5.40+54.7%+1.8%$1.24B$862.40M0.004,827 Related Companies and Tools Related Companies WVE Competitors ETNB Competitors TLRY Competitors PGEN Competitors RCUS Competitors NTLA Competitors GPCR Competitors XERS Competitors ABCL Competitors EVO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALDX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
